Reflecting the important role of ADO in the tumor context, CD39, CD73, and CD38 ectoenzymes have been identified as potential biomarkers for clinical outcomes in chemo- and immune-therapies and to identify immune subsets that may be responsible for immunosuppression or are in an exhausted state. Here, ENTPD1 is linked to neoplasm.